Pharmaceutical packaging market insight is projected to grow from approximately US $159.31 billion in 2025 to US $397.71 billion by 2034, representing a CAGR of ~10.7 % over the forecast period. This growth reflects expanding pharmaceutical manufacturing, diversification of drug-delivery modes, regulatory pressures (such as serialization and anti-counterfeiting), and increasing demand for advanced, sustainable, and smart packaging solutions.
In 2024, the North America region held the largest share of the pharmaceutical packaging market (estimates around ~30-36 % of global volume/value).
The Asia-Pacific region is expected to record the fastest growth rate during the forecast period, driven by countries such as China and India with strong generics manufacturing bases and increasing healthcare spending.
Europe continues to grow at a steady pace, underpinned by stringent regulatory frameworks (e.g., the EU Falsified Medicines Directive) and growing sustainability focus.
Download a Sample of Our Market Intelligence: https://www.towardspackaging.com/download-sample/5050
Material: Plastics & polymers (including polyethylene [PE], polypropylene [PP], polyvinyl chloride [PVC]) dominated the market in 2024, offering cost-efficiency, lightweight transport advantages and strong barrier properties.
Product: Primary packaging (i.e., the immediate container/packaging of the drug) held the largest share in 2024, given that each dosage unit requires packaging that ensures purity, stability, and compliance.
Drug-delivery mode: Oral drugs (tablets, capsules, syrups, sachets) dominated in 2024, due to their large volumes, lower manufacturing complexity and higher patient acceptance.
End-use: The pharmaceutical manufacturing segment (including in-house packaging by pharma companies and packaging by contract packagers) was the leading end-use segment in 2024—a function of rising drug production and outsourcing to CPOs/CDMOs.
Escalating demand for pharmaceutical products and increased healthcare spending are driving packaging volumes – for chronic diseases, ageing populations, biologics, specialty therapies, as well as online pharmaceutical sales.
Growth in biologics and gene therapies is increasing demand for sophisticated packaging (e.g., cold-chain, injectables, speciality vials and syringes).
Smart and connected packaging (via NFC, IoT sensors, machine-vision, AI) is gaining traction to improve patient adherence, supply-chain visibility and anti-counterfeiting.
Sustainability demands are pushing packaging suppliers to adopt bio-based polymers, recycled content, lightweighting, and mono-material designs.
Stringent and evolving regulatory requirements (e.g., from the U.S. Food & Drug Administration (FDA), European Medicines Agency (EMA)) increase the cost and complexity of packaging development and qualification.
Anti-counterfeiting and track-and-trace mandates impose additional cost burdens on packaging systems.
The tension between sustainability goals and the high barrier/hygiene requirements of pharmaceutical packaging presents technical challenges (for example, substituting plastic materials without compromising integrity).
The rise of smart and connected packaging offers a meaningful opportunity: embedding sensors, IoT connectivity and AI in primary and secondary packaging to enable real-time monitoring, dosage tracking, condition monitoring and supply-chain visibility.
Expansion of biologics, personalised medicine, injectables and high-value therapies opens up new packaging segments (premium vials, pre-filled syringes, auto-injectors) that command higher margins.
Emerging markets (Asia-Pacific, Latin America, MEA) provide high-growth potential as local manufacturing expands and global pharma supply-chains diversify.
Plastics & polymers led in 2024 (estimated ~35-45 % share of global value), due to scalability, cost-effectiveness and barrier performance. Glass, paperboard/foil and other materials make up the remainder, with glass dominant in injectables, paperboard/foil common in cartons and secondary/tertiary packaging.
Primary packaging (for example bottles, blister packs, vials, ampoules) accounted for the largest share in 2024. Secondary packaging (cartons, labels) and tertiary packaging (outer boxes, shipping containers) grow in importance driven by serialization and supply-chain logistics.
The oral drug-delivery mode remains the largest (tablets, capsules, syrups, etc.). Injectables, ocular, nasal, pulmonary and topical segments are expanding rapidly (especially injectables/biologics) due to higher growth in specialty therapies.
The pharmaceutical manufacturing segment (in-house packaging + outsourced CPO/CDMO packaging) dominated in 2024. Retail and institutional packaging segments also matter, but the manufacturing base drives the largest volume and value of packaging.
North America largest share in 2024 (advanced infrastructure, regulatory rigour, high per-capita drug consumption).
Asia-Pacific fastest growth region (strong generics capacity, favourable policies, modernization of healthcare).
Europe steady growth (stringent regulation, sustainability focus).
Latin America and MEA represent smaller shares currently but hold expansion potential as pharmaceutical manufacturing and access improve.
Below are leading players in the global pharmaceutical packaging market and their key profiles:
Market Share: ~15.20 % in 2024
EBITDA Margin: ~18.70 % in 2024
About: Amcor is a global packaging company that develops and produces flexible packaging, rigid containers, specialty cartons, closures and services for food, beverages, pharmaceuticals, medical devices, home and personal-care products.
Products: Flexible films, rigid plastic containers, closures, specialty cartons, medical/pharma packaging solutions, drug-delivery system supports.
Market Cap: ~US $18.3 billion (as of late 2025)
Commentary: Amcor’s acquisition of Berry Global in 2024 significantly boosted its position in the pharmaceutical packaging sector (via plastic solutions) and complements its scale and sustainability credentials.
Market Share: ~13.50 % in 2024
EBITDA Margin: ~17.20 % in 2024
About: Gerresheimer is a German manufacturer specialising in primary packaging products and drug-delivery devices (glass and plastic) for the pharmaceutical and cosmetics industries. Founded in 1864, headquartered in Düsseldorf, with global operations in 16+ countries.
Products: Glass vials, ampoules, cartridges, pre-filled syringes, injection devices, plastic primary packaging for pharma.
Market Cap: ~US $1.1–1.4 billion (as of 2025) depending on currency and source.
Commentary: Gerresheimer’s acquisition of Bormioli Pharma bolstered its glass packaging portfolio for injectables/biologics, addressing rising demand for specialty drug containment.
Market Share: ~11.80 % in 2024
EBITDA Margin: ~15.50 % in 2024
About: Schott Pharma (a division of Schott AG) specialises in high-quality glass packaging solutions and drug-delivery systems, particularly for biologics and injectables. Headquartered in Mainz, Germany.
Products: Borosilicate glass vials, syringes, cartridges, high-value packaging for injectable and biologic pharmaceuticals.
Market Cap: ~€2.9 billion (~US $3 billion) as of Nov 2025.
Commentary: With its strong glass-packaging heritage and focus on biologics containment, Schott Pharma is well-positioned in the higher-value injectable segment.
Market Share: ~10.50 % in 2024
EBITDA Margin: ~14.80 % in 2024
About: West is a key player in injectable drug-delivery systems and packaging components, with strong innovation in closures, vials, syringes and advanced delivery solutions.
Products: Elastomer components, containment systems, auto-injector platforms, syringe systems, packaging components for biologics and injectables.
Market Cap: (publicly listed; detailed figure not provided here)
Commentary: West’s leadership in the injectable and biologics delivery systems market aligns with growing specialty pharmaceuticals and high-margin packaging demand.
Market Share: ~9.70 % in 2024 (prior to its acquisition by Amcor)
EBITDA Margin: ~13.90 % in 2024
About: Berry Global is a diversified plastic packaging manufacturer with strong presence in healthcare/pharma packaging prior to its merger with Amcor.
Products: Rigid plastic containers, closures, healthcare-grade packaging solutions, primary/secondary packaging for pharmaceuticals.
Commentary: The integration into Amcor is expected to create synergies, scale and broaden the combined entity’s offerings in pharmaceutical packaging.
Market Share: ~8.30 % in 2024
EBITDA Margin: ~12.40 % in 2024
About: AptarGroup specialises in drug-delivery and packaging solutions with emphasis on patient-centric design, inhalation, nasal, topicals, auto-injectors and specialty formats.
Products: Drug-delivery systems (inhalers, auto-injectors), specialized packaging components, patient-centric packaging solutions.
Commentary: Aptar’s focus on advanced delivery formats positions it well in growth areas of pharmaceutical packaging beyond traditional primary containers.
Market Share: ~6.20 % in 2024
EBITDA Margin: ~11.30 % in 2024
About: SGD Pharma is a global supplier of high-quality glass vials and bottles for the pharmaceutical industry, particularly in Europe and Asia.
Products: Glass vials, bottles, primary containment systems for injectables and lyophilisation.
Commentary: With the shift towards biologics, contract manufacturing and heightened containment requirements, SGD is positioned in a growth niche.
Market Share: ~5.80 % in 2024
EBITDA Margin: ~10.60 % in 2024
About: Catalent primarily provides contract development and manufacturing (CDMO) services, including packaging and finishing services for pharmaceuticals.
Products: Blister packs, bottles, specialty packaging formats, finishing services for oral, injectable and complex dosage forms.
Commentary: As more pharma companies outsource packaging and finishing operations, Catalent’s packaging offerings within its CDMO portfolio gain importance.
Market Share: ~5.10 % in 2024
EBITDA Margin: ~9.80 % in 2024
About: Alpla is a global plastic packaging specialist with strong presence in rigid plastics. Its offerings extend into pharmaceutical packaging solutions.
Products: Rigid bottles, closures, high-performance plastic containers for pharma, personal care, consumer goods.
Commentary: With plastics & polymers dominating material share, Alpla’s plastic-packaging focus is well aligned with key market material trends.
Market Share: ~4.90 % in 2024
EBITDA Margin: ~9.10 % in 2024
About: Bormioli Pharma, now part of Gerresheimer, specialises in glass pharmaceutical packaging (vials, ampoules, cartridges).
Products: Type I borosilicate glass vials, injection cartridges, ampoules, primary containment systems for injectable drugs.
Commentary: The acquisition by Gerresheimer strengthens the combined portfolio in glass packaging and biologics-oriented markets.
Note: ‘Others’ (smaller players) account for ~9.20 % of the market in 2024.
Source share and margin data as per provided report details.
Based on the forecast to 2034 (USD 397.71 billion), the market is expected to more than double from 2025. Key transformation areas include:
A shift in materials: although plastics & polymers remain dominant, growth of glass (especially for injectables/biologics), paperboard/foil in secondary/tertiary packaging, and hybrid/material innovations will influence the mix.
Packaging for specialty therapies (injectables, gene therapies, biologics) will grow faster than volume-based oral packaging, leading to higher value per unit.
Smart and connected packaging, serialization and anti-counterfeiting features will become standard, adding value beyond simple containment.
Ecosystem convergence: packaging suppliers partnering with drug-delivery/biologics companies, CDMOs and technology providers to offer integrated containment + delivery solutions.
Regional shift: Asia-Pacific growth will gradually increase its share of global market value, narrowing the gap with North America and Europe. Emerging markets will also see investment in local manufacturing, packaging infrastructure and regulatory alignment.
North America will continue to lead in absolute terms, but Asia-Pacific offers the highest growth potential.
Plastics & polymers traditional dominance will remain, but glass and specialty materials will witness accelerated growth in the injectables/biologics space.
Primary packaging remains the backbone of the market, but secondary and tertiary packaging (and associated value-added features like sensors, connectivity, traceability) will gain importance.
Oral drug delivery still offers the largest base, but injectables, ocular, nasal and pulmonary delivery forms will grow faster, altering packaging requirements and value.
Major packaging incumbents are investing through acquisitions and partnerships (e.g., Amcor-Berry) to gain scale, broaden capabilities and meet sustainability / advanced-packaging demands.
Sustainability, digitalisation and regulatory compliance (track-and-trace, anti-counterfeiting) will remain fundamental themes shaping packaging innovation and cost structures.
Suppliers with strong capabilities in advanced materials (glass, high-barrier plastics), drug-delivery integration (auto-injectors, pre-filled syringes), and digital features (sensors, connectivity) are well-positioned.
Packaging design will increasingly be used as a differentiator for drug manufacturers (patient-centric design, personalised packaging, smaller batch sizes for specialty therapies).
Emerging markets manufacturing growth presents opportunities for local partnerships, low-cost scalable packaging solutions and regional supply-chain diversification.
Suppliers need to balance sustainability goals with strict pharmaceutical barrier and hygiene requirements — innovative mono-materials, recycled content, lightweighting and closed-loop systems will become competitive advantages.
Outsourced packaging services (by CDMOs, contract packagers) will gain importance as drug manufacturers focus on core R&D and manufacturing; packaging suppliers may need to offer end-to-end solutions (design, components, finishing, serialization, value-added services).
1. What is driving the rapid growth of the pharmaceutical packaging market?
The key growth drivers include rising pharmaceutical production (driven by chronic disease, ageing populations, biologics, gene therapies), expansion of packaging volumes (each dose unit requires packaging), increased regulatory demands (serialization, tamper-evidence, track-and-trace), adoption of smart/connected packaging and growth in emerging markets manufacturing.
2. Which region is expected to grow the fastest in the pharmaceutical packaging market?
The Asia-Pacific region is expected to grow at the fastest rate over the forecast period, due to strong generics manufacturing bases (for example India and China), favourable government policies boosting local pharma production, increasing healthcare infrastructure investment, and rising domestic and export demand for packaged pharmaceuticals.
3. Why do plastics & polymers dominate the material segment?
Plastics & polymers dominate because they offer cost advantages, scalability, lightweight transport, good barrier properties (moisture, oxygen, light), fit mass-production needs, and are versatile in design (closures, blister packs, bottles). These advantages give plastics a larger share compared to glass, paperboard/foil or specialty materials in many pharmaceutical packaging applications.
4. How are sustainability and regulations influencing pharmaceutical packaging?
Sustainability demands (reduced plastic waste, recycled content, bio-based polymers, lightweighting) are pressuring packaging suppliers to innovate. Simultaneously, regulations (such as the FDA’s serialization requirements, the EU Falsified Medicines Directive) require packaging systems with track-and-trace, tamper-evidence and anti-counterfeiting features. Suppliers must therefore design packaging that meets both environmental goals and high safety/barrier standards—this creates cost, design and material complexity.
5. Which companies are leading the pharmaceutical packaging market and what distinguishes them?
Leading companies include Amcor plc (~15.2 % share, ~18.7 % EBITDA margin), Gerresheimer AG (~13.5 % share, ~17.2 % EBITDA margin), Schott Pharma AG & Co. (~11.8 % share, ~15.5 % EBITDA margin), West Pharmaceutical Services, Berry Global Inc., AptarGroup Inc., SGD Pharma, Catalent Inc., Alpla Werke Alwin Lehner GmbH and Bormioli Pharma (~4.9 % share). These companies are distinguished by scale, innovative packaging technologies (especially for specialty/biologic drugs), strong global footprints, and strategic acquisitions or partnerships to address sustainability, smart-packaging and regulatory demands.
Source : https://www.towardspackaging.com/insights/pharmaceutical-packaging-market
Access our exclusive, data-rich dashboard dedicated to the respective market built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access Now: https://www.towardspackaging.com/contact-us
Become a Valued Research Partner with Us – Schedule a meeting: https://www.towardspackaging.com/schedule-meeting
Request a Custom Case Study Built Around Your Goals: sales@towardspackaging.com
About Us
Towards Packaging is a global consulting and market intelligence firm specializing in strategic research across key packaging segments including sustainable, flexible, smart, biodegradable, and recycled packaging. We empower businesses with actionable insights, trend analysis, and data-driven strategies. Our experienced consultants use advanced research methodologies to help companies of all sizes navigate market shifts, identify growth opportunities, and stay competitive in the global packaging industry.
Stay Connected with Towards Packaging:
Our Trusted Data Partners
Precedence Research | Statifacts | Towards Healthcare |TowardsAuto | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire | Nutraceuticals Func Foods | Onco Quant | Sustainability Quant | Specialty Chemicals Analytics
The resealable beverage can market is witnessing significant growth, with demand expected to surge from…
The global HDPE (High-Density Polyethylene) packaging solutions market is projected to witness a robust growth…
The growing concerns about environmental sustainability have led to a dramatic shift in consumer behavior…
The stand-up pouch market has witnessed an impressive expansion and is expected to grow significantly…
The growing global demand for sustainable and eco-friendly packaging solutions has given rise to the…
In recent years, the demand for sustainable and eco-friendly packaging solutions has been growing rapidly,…